BRAF and non-small cell lung carcinoma: Beyond TMB, limited gene panels have also demonstrated predictive power for immunotherapy response using algorithms such as the “high immune score.” The absence of targetable driver mutations (EGFR, ROS1, ALK, BRAF V600E) and of PTEN or STK11 mutations, combined with the presence of KRAS or TP53 transversion mutations, has been correlated with favorable ICI response in advanced NSCLC [68].